Reading CAMP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CAMP free→
CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Watch· this week
$3.96-5.49%
Close 2026-06-15 · 1-day change
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is neutral, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, but risk is high, and the sector backdrop is a headwind, with CAMP compared to sector peers being below typical. Peer multiples imply a price about 143% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. Key factors to watch include potential guidance cuts and sector trends, as these could significantly impact CAMP's performance. This read is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $217.57M
- Employees
- —
- IPO date
- 2024-09-20
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.96. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$1.63consensus
Range $1.14 – $2.12
vs price: +143% above
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearexpensive
$2.53consensus
Range $1.97 – $3.09
vs price: +56% above
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearfull
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Optionality premiumlow confidence
At $3.96, CAMP's earnings are too small for P/E to mean much; on sales it trades at 58× p/s (6.2× the 9× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $1.61 fair value covers only the as-is business, low confidence. Not investment advice.
Multiple (P/S)
58.3x
peer 9.4x · own history —
Premium
6.2x peer
Growth the price needs
146%
our forecast —
Our fair value
$1.61
range $1.13 – $2.10
WhyPeer anchor understates a real premiumOptionality our model can't price
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced in
The market is pricing in roughly 146% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Elevated fragilityrisk posture, not a price call
Flags: expensive valuation, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
38th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.30x of net income into operating cash flow.
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
Management & capital allocation
neutral8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
37th pctl · Health Care
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bullishEPS revised +3.2% / 30d, n=3for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.20 → $-0.20 (+3.2% / 30d). 2 raised, 0 cut, 3 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 86% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 62.1% above current price.
Material events
0 positive, 0 negative / 30d.
Sector context
Intermediate · WeeklySector phase: health care is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weakProvisional
- Capital allocation
- weak
- Earnings discipline
- weak
- Margin discipline
- neutral
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-15
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$315.
How much price usually moves either way.
On a bad day, this stock has moved -$948.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,175.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- Either wayMedium confidenceQuartersactive 4d
Watch for sector performance trends in Health Care
Why it matters: CAMP operates in a maturing sector. Changes in sector growth can impact CAMP's performance and investor sentiment.
What confirms / what disproves
Confirms one read:Health Care sector revenue growth re-accelerates back toward its highs.
Confirms the other:Sector growth continues to slow down. This shows wider problems in the Health Care industry.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CAMP yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting CAMP and other Healthcare names. Worth watching these names for early signals.
- If CAMP raises forward guidance on the next earnings call (currently NEW as of 2026-05-14), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for CAMP and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If CAMP cuts guidance on the next call (currently NEW as of 2026-05-14), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping CAMP and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-125d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Amendment to 2024 Equity Incentive Plan On June 10, 2026, at the annual meeting of stockholders (the “Annual Meeting”) of CAMP4 Therapeutics Corporation (the “Company”), the stockholders of the Company approved an amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan (the “2024 Plan”) to amend the evergreen provision to pro…
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
About the same as last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.